Statistical Analysis
Statistical analysis was conducted from August 2016 to September 2022. All enrolled patients who received at least 1 dose of IT GLA-SE were included in the safety analysis. Descriptive statistics were used to summarize baseline patient characteristics, safety, clinical response, and immunologic response variables. Local response was measured as percent change of the maximum dimension of the target lesion. For local response comparison between target lesions and concomitant irradiated or untreated lesions, means were calculated by pooling local response at last follow-up for all lesions among evaluable patients (n = 3). Statistical analysis was performed using Microsoft Excel, version 16 (Microsoft Corp) and GraphPad Prism, version 9 (GraphPad Software Inc).